EGFR and cancer: Thus, combined inhibition of MEK and their upstream kinases (e.g., RAF, RAS, EGFR, etc.)are expected to enhance MAPK signaling inhibition and show better clinical efficacy than monotherapy in RAS mutant cancers, as did in clinical trials now.